Implied Podcast
Season 1
by Implied Podcast™
Reddit just shed nearly 10% of its value in a single session, caught in a brutal tug-of-war between Wall Street analysts. While bulls recently slapped a $320 target on the stock for its AI data potential, a stinging new report warns that the core ad business is cracking as small businesses pull back. With a massive 65 P/E ratio "priced for perfection" and executives unloading shares right before the drop, the market is suddenly terrified. In this episode of Implied, we break down the mixed signals and ask: Is this a discount on a future tech giant, or a falling knife you shouldn’t catch?
Trip.com just nose-dived nearly 20% overnight, blindsiding investors with a sudden antitrust investigation from Chinese regulators. It was supposed to be the "safe" bet in Chinese tech, riding high on a post-pandemic travel boom and new visa-free policies—but now, fears of a renewed crackdown are back. In this episode, we break down why the "King of Travel" is under fire, what a potential breakup of its dominance means for the stock, and whether this massive drop is a discount or a value trap.
Dave Inc. (DAVE) just capped off a brutal week, plunging nearly 23% amid Fed controversy and fears of new banking regulations. The twist? The company just refinanced its debt and analysts argue it has zero exposure to the fees driving the market panic. In this episode, we break down the massive disconnect between Dave’s crashing stock price and its booming 63% revenue growth. Is this a "mistaken identity" sell-off creating a rare discount, or is it dangerous to catch a falling knife in this volatile sector? Dive in to see why the facts might contradict the fear.
Figma, the design powerhouse that nearly merged with Adobe for $20 billion, is now trading around $36—a staggering 75% drop from its $142 post-IPO high. But don't let the price tag fool you. While the stock looks like a "broken IPO," the business is hitting massive milestones, including crossing the $1 billion annual revenue run rate with 38% growth. In this episode of Implied, we peel back the curtain on why a $1.1 billion paper loss is masking a cash-rich company with $1.5 billion on the sidelines. We explore how Figma’s acquisition of the AI startup Weavy is turning the tables on Adobe and why a 131% net dollar retention rate makes this one of the stickiest products in tech history. Is this a valuation trap at 18x sales, or a rare chance to buy a generational leader at a deep discount? Tune in for the full breakdown of Figma’s wild 2026 trajectory.
Abercrombie & Fitch just saw an 18% hole blown in its stock chart, despite reporting record holiday demand. Why the panic? Wall Street is fixating on a new $90 million tariff bill and rising capital expenses, ignoring the brand’s massive turnaround success. In this episode, we break down why "good" isn't good enough for this market anymore and analyze the setup: is this a warning signal for retail margins, or a massive "sell-the-news" overreaction that created a buying opportunity?
Coty shares are seeing ghosts, trading near 52-week lows at $3.06 after being practically cut in half over the last year. Despite a massive $750 million cash injection from selling its Wella stake, Wall Street is terrified by a sudden CEO shakeup and a wider crisis hitting rival Estée Lauder. In this episode, we break down why the market hates the uncertainty—and why they might be missing the massive debt paydown happening behind the scenes. Is this a "falling knife" or a cleaner company trading at rock-bottom multiples? Tune in to find out if this is the end of the line or the ultimate value play.
American International Group just surrendered months of gains, shedding nearly 10% in a bloodbath week after a surprise "reserve strengthening" announcement. Investors are fleeing as fears mount that the insurer’s underwriting models are fundamentally broken and "structural damage" has been done. In this episode of Implied, we break down the critical "Combined Ratio" miss, why the market is having 2008 flashbacks, and the risk of "cockroach theory." Is this a rare chance to buy a blue-chip at book value, or is the bleeding just getting started? Dive in to find out why you shouldn't catch this falling knife just yet.
Regencell Bioscience (RGC) just went from a massive 60% rally to a sudden 20% plunge in less than 24 hours—and there is absolutely zero news to explain it. Despite having a market cap floating around $10 billion, the company has generated effectively no revenue and is trading at a staggering 5,000x book value. In this episode, we break down the dangerous mechanics behind this "roller coaster," the shadow of a DOJ probe, and why this stock is behaving less like an investment and more like a "lottery ticket in a burning building."
SiTime just erased $1 billion in market value in a single session, falling over 10% despite being the heartbeat of modern AI infrastructure. The stock has been a rocket ship—up 56% in the last year—but today it sliced through key technical levels as investors finally questioned its astronomical valuation. Is this a disastrous breakdown, or a rare chance to buy the "Endura" defense play at a discount? In this episode, we analyze whether this massive selloff is just a shakeout of the "tourists" or a warning not to catch a falling knife.
Just 24 hours ago, D-Wave Quantum was flying high on CES 2026 news—but today, the stock crashed nearly 10%. Why? A top executive just unloaded $24 million worth of shares right into the rally. In this episode of Implied, we break down whether this massive insider sale signals a lack of confidence or just a smart cash-out. With an $11 billion valuation on just $3.74 million in quarterly revenue, is the quantum bubble bursting, or will upcoming government contracts save the day? Tune in to find out why you might want to wait before buying this dip.